When investors seek to inject growth momentum into their portfolios, tech stocks are often the first choice. Companies like ...

A leading expert offers his verdict on CSL shares. The post Should you buy today's big dip on CSL shares amid the $750 ...

The pharmaceutical giant has avoided a board spill, but 42 per cent of shareholders voted against executive remuneration in a ...

Australian biotech giant CSL has delayed its vaccine division spin-off due to a drastic decline in US flu immunization rates, leading to a 16.6% drop in share price. The company's revenue and profit ...

SYDNEY (Reuters) -Australian biotech CSL has cut its profit outlook and delayed plans to spin off its vaccine division, blaming an unprecedented fall in U. flu immunisation rates, which knocked its ...

(Reuters) -Australian biotech CSL on Tuesday delayed its planned vaccine division spin-off and cut earnings forecasts due to a bigger-than-expected decline in U.S. flu vaccination rates, sending its ...

Another major investment by ARK was the acquisition of 385,585 shares of Block Inc (NYSE:XYZ), a financial services and mobile payment company formerly known as Square, with a total value of ...

CSL has put the demerger of its Seqirus vaccination division on ice and cut its sales and profit forecasts due to a pullback ...

Dyne Therapeutics (NASDAQ: DYN) had a Monday neither it nor its investors will ever forget. This wasn't of its own making, ...

Dyne Therapeutics’ stock sees record rally, but one analyst says it could still climb a lot further, after a rival got bought ...